Glanzmann thrombasthenia (GT) is a rare congenital platelet function disorder associated with a severe bleeding diathesis. Thrombotic manifestations remain a rare condition. We report here the first case of recurrent venous thromboembolism (VTE) successfully treated with apixaban in a patient with GT. Our patient’s morbid obesity was an additional challenge. The Key Clinical Question was to determine if direct oral anticoagulants are suitable for patients with both obesity and GT. In our patient, the first episode of VTE occurred after the use of a low dose of activated recombinant factor VII for a minor procedure, whereas the second was unprovoked. Administration of rivaroxaban very quickly led to the appearance of bleeding symptoms and subsequently led to poor compliance and extension of deep vein thrombosis. The patient was switched to apixaban, with very good efficacy and safety over the cumulative 18 months of use. The last updated guidelines now recommend the use of rivaroxaban and apixaban for management of VTE in patients with obesity. Regarding patients with GT, there is still insufficient data on the use of direct oral anticoagulants. Management of thrombotic manifestations in these patients remains a rare and complex condition and could be improved by the creation of a specific international registry.
PF4-dependent disorders encompass a heterogeneous group of immune-mediated thrombotic syndromes, including heparin-induced thrombocytopenia (HIT), its autoimmune variants such as spontaneous HIT, and vaccine-induced immune thrombotic thrombocytopenia (VITT). The recent identification of VITT and VITT-like entities has significantly expanded the diagnostic spectrum, complicating the retrospective interpretation of cases that occurred before their formal recognition. We report the case of a young patient who initially presented with a clinical and biological presentation suggestive of atypical HIT, at a time when neither spontaneous HIT nor VITT were defined. The patient was re-evaluated during the COVID-19 vaccination campaign, prompting a reassessment of the initial diagnosis in light of current knowledge on PF4-related disorders, which continue to increase in both diversity and complexity. A critical review of clinical and laboratory findings now favors a diagnosis of VITT-like syndrome over spontaneous HIT, although confirmatory testing is no longer feasible given the time elapsed since the acute phase. This case highlights the importance of revisiting historical cases using updated diagnostic criteria to improve the identification and management of these emerging and underrecognized syndromes.
The obstetrical follow-up of patients with a severe hypofibrinogenemia requires a multidisciplinary collaboration because of potential maternal-fetal complications (recurrent miscarriages, intrauterine fetal demise, post-partum hemorrhage, thrombosis). We report the obstetrical management of a multiparous patient with a severe congenital hypofibrinogenemia associated with a platelet disorder (abnormal phospholipid externalization). A therapeutic strategy based on a biweekly administration of fibrinogen concentrates associated with enoxaparin and aspirin allowed the maintenance of pregnancy. But this last one got complicated by a placenta percreta requiring a salvage hysterectomy with an appropriate hemorrhage prophylaxis.